Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-Dehydroepiandrosterone (1-DHEA) is a synthetic, orally active anabolic-androgenic steroid (AAS) and a positional isomer of the naturally occurring hormone dehydroepiandrosterone (DHEA). It functions as a prohormone, undergoing enzymatic conversion in the body via 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase into 1-testosterone (dihydroboldenone) and 1-androstenedione. Unlike 5-DHEA, 1-DHEA does not aromatize to estrogen, as its primary metabolite, 1-testosterone, is not a substrate for the aromatase enzyme. This characteristic makes it a popular 'designer steroid' in the bodybuilding community for promoting lean muscle mass gains without associated estrogenic side effects such as gynecomastia or water retention. It is primarily marketed as a dietary supplement and is not currently approved by the FDA for any medical indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-dehydroepiandrosterone.